News &amp; Updates

Phase II data presented at CROI 2024 demonstrated the ability of an investigational, long-acting, oral once-weekly regimen comprising islatravir, a nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class capsid inhibitor, to maintain viral suppression at week 24 in virologically suppressed people living with HIV (PWH).

11 Mar 2024

CU Medicine aims to reach global top 20 in 10 years

The new Dean of Medicine at the Chinese University of Hong Kong (CU Medicine), Professor Philip Chiu, aspires to guide the Faculty of Medicine to become one of the global top 20 medical schools in 10 years.

Simple, radical hysterectomies for low-risk cervical cancer yield similar recurrence rate

Simple hysterectomy shows noninferiority over radical hysterectomy for patients with low-risk cervical cancer, with no significant difference in the 3-year incidence of pelvic recurrence, while reducing the risk of urinary incontinence or retention, according to the phase III CX.5 SHAPE trial.

Twin study: Adverse childhood experiences linked to poor adult mental health outcomes

Adverse childhood experiences (ACEs) are associated with depression, anxiety, substance use disorder, and stress-related disorders in adulthood, a twin cohort study has shown.

11 Mar 2024

TRuE-AD3: Ruxolitinib cream effective in children with AD

Ruxolitinib cream, a topically administered selective Janus kinase 1/2 inhibitor, appears to be effective for mild-to-moderate atopic dermatitis (AD) in children aged 2–11 years, according to the TRuE-AD3 trial presented at AAAAI 2024.

Sports therapy alleviates menopause symptoms

Women undergoing menopause may benefit from sports therapy, which has been shown to improve somatic and urogenital symptoms as well as lift depressive moods, according to a study.

$Benralizumab noninferior to mepolizumab for relapsing, refractory EGPA$

Benralizumab noninferior to mepolizumab for relapsing, refractory EGPA

10 Mar 2024 by

Benralizumab compares favourably with mepolizumab for inducing remission in adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA), as shown in the results of the head-to-head phase III MANDARA trial.

Cefepime–taniborbactam bests meropenem for complicated UTI

10 Mar 2024 by

Patients with complicated urinary tract infection (UTI) may fare better with cefepime–taniborbactam than with meropenem, with the combination having been associated with much higher treatment success rates in the phase III CERTAIN-1 trial.

10 Mar 2024

Are you eating the right plant-based diet?

Not all plant-based diets are good for the body, and adherence to an unhealthful type may negatively affect gut microbiome diversity, composition, and metabolites, suggests a study.